Vaccinex, Inc.

NasdaqCM VCNX

Vaccinex, Inc. Price to Earnings Ratio (P/E) on January 14, 2025

Vaccinex, Inc. Price to Earnings Ratio (P/E) is NA on January 14, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Vaccinex, Inc. 52-week high Price to Earnings Ratio (P/E) is NA on January 14, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Vaccinex, Inc. 52-week low Price to Earnings Ratio (P/E) is NA on January 14, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Vaccinex, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is NA.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: VCNX

Vaccinex, Inc.

CEO	Dr. Maurice Zauderer Ph.D.
IPO Date	Aug. 9, 2018
Location	United States
Headquarters	1895 Mount Hope Avenue
Employees	37
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Key trends

Past 5 years